According to a new study, dupilumab has been shown to reduce severity and improve quality of life (QoL) in pediatric patients with atopic dermatitis (AD) two weeks after treatment.
top of page
it's where dermatology lives
bottom of page
According to a new study, dupilumab has been shown to reduce severity and improve quality of life (QoL) in pediatric patients with atopic dermatitis (AD) two weeks after treatment.